Drugs / Diphtheria Antitoxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06053853 | Jan → May 2023 | — | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diphtheria Antitoxin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06053853 ↗ |
| Known as | DAT | “Post Marketing Surveillance of Diphtheria Antitoxin (DAT)” NCT06053853 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2108417 ↗ |
| Route | Intravenous | “Administered intravenously.” NCT06053853 ↗ |